Hence, bioactive peptidescotargeting GCGR and GLP-1R may remediate the blood glucose and fattyacid metabolism imbalance, tackling both diabetes and obesity to supersedecurrent monoagonist therapy. The gene discussed is GCGR; the disease is obesity disorder.